title: FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
abstract: We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.
authors.affiliation: Divisione di Ematologia, Ospedali Riuniti Bergamo, Bergamo, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Carlotti
authors.forename: Giuseppe A
authors.initials: GA
authors.lastname: Palumbo
authors.forename: Elena
authors.initials: E
authors.lastname: Oldani
authors.forename: Daniele
authors.initials: D
authors.lastname: Tibullo
authors.forename: Silvia
authors.initials: S
authors.lastname: Salmoiraghi
authors.forename: Andrea
authors.initials: A
authors.lastname: Rossi
authors.forename: Josee
authors.initials: J
authors.lastname: Golay
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pulsoni
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000032:analysis / Q000235:genetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D005838:Genotype; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000032:analysis; D007167:Immunotherapy; D053208:Kaplan-Meier Estimate; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011241:Prednisone / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D017452:Receptors, IgG / Q000032:analysis / Q000235:genetics*; D000069283:Rituximab; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D014408:Biomarkers, Tumor; C496124:FCGR3A protein, human; C080568:Fc gamma receptor IIA; D007143:Immunoglobulin Heavy Chains; D019253:Proto-Oncogene Proteins c-bcl-2; D017452:Receptors, IgG; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone